The stock of Eleven Biotherapeutics Inc (NASDAQ:EBIO) is a huge mover today! The stock decreased 2.44% or $0.07 during the last trading session, hitting $2.8. About 469,023 shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 849.15% since February 29, 2016 and is uptrending. It has outperformed by 838.73% the S&P500.
The move comes after 9 months negative chart setup for the $54.39M company. It was reported on Oct, 1 by Barchart.com. We have $2.52 PT which if reached, will make NASDAQ:EBIO worth $5.44M less.
Analysts await Eleven Biotherapeutics Inc (NASDAQ:EBIO) to report earnings on November, 2.
Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage
Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. The rating was downgraded by Leerink Swann on Tuesday, January 19 to “Market Perform”. Leerink Swann maintained the stock with “Outperform” rating in Saturday, August 15 report. Citigroup downgraded the stock to “Neutral” rating in Tuesday, January 19 report. The firm has “Neutral” rating given on Wednesday, March 16 by Citigroup.
According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.62, from 0.38 in 2016Q1. The ratio is positive, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.
Susquehanna Int Gp Ltd Liability Partnership last reported 0% of its portfolio in the stock. Royal National Bank Of Canada accumulated 0% or 500 shares. Guggenheim Ltd last reported 0% of its portfolio in the stock. Blackrock Institutional Trust Communications Na reported 149,618 shares or 0% of all its holdings. National Bank Of New York Mellon Corp owns 67,483 shares or 0% of their US portfolio. Renaissance Tech Ltd Liability Company owns 118,500 shares or 0% of their US portfolio. National Bank Of America Corporation De has 35 shares for 0% of their US portfolio. Two Sigma Securities Limited Liability Co, a New York-based fund reported 25,428 shares. Gp One Trading L P, a Illinois-based fund reported 600 shares. Kcg Holding has 32,907 shares for 0% of their US portfolio. Vanguard Gp, a Pennsylvania-based fund reported 77,656 shares. The New York-based Morgan Stanley has invested 0% in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Blackrock Fund holds 1,624 shares or 0% of its portfolio. Goldman Sachs has 0% invested in the company for 13,343 shares. Citigroup last reported 600 shares in the company.
More recent Eleven Biotherapeutics Inc (NASDAQ:EBIO) news were published by: Marketwatch.com which released: “Eleven Biotherapeutics stock up 25% on news of Viventia Bio purchase” on September 21, 2016. Also Businesswire.com published the news titled: “Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein …” on September 21, 2016. 247Wallst.com‘s news article titled: “Can Eleven Biotherapeutics Keep Climbing With This Roche Deal?” with publication date: August 16, 2016 was also an interesting one.
EBIO Company Profile
Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.